Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Immunol., 04 February 2026

Sec. Viral Immunology

Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1795238

Correction: HIV subtype-specific gp140-CD4 binding, Temsavir efficacy, and identification of novel adhesion inhibitors against Chinese HIV strains

This article is a correction to:

  1. HIV subtype-specific gp140-CD4 binding, Temsavir efficacy, and identification of novel adhesion inhibitors against Chinese HIV strains

    1. Read original article
Tianyang Liu,&#x;Tianyang Liu1,2†Xiaowen Li,,&#x;Xiaowen Li1,2,3†Xiaolin YangXiaolin Yang2Shengjie Zhang,Shengjie Zhang4,5Yao Wang,,Yao Wang1,2,6Siwei Zhang,Siwei Zhang1,2Lin Cheng,Lin Cheng1,2Shanshan Tang,Shanshan Tang1,7Fuxiang Wang,*Fuxiang Wang4,5*Yao Zhao*Yao Zhao2*Hongzhou Lu,*Hongzhou Lu2,8*Lanlan Wei*Lanlan Wei1*
  • 1Institute for Hepatology, Shenzhen Third People’s Hospital, The Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, Guangdong, China
  • 2National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, The Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China
  • 3Department of Biology, School of Medicine, Institute for Infectious Disease, Southern University of Science and Technology, Shenzhen, China
  • 4Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Clinical Research Center for Infectious Disease, Shenzhen, China
  • 5State Key Discipline of Infectious Disease, Shenzhen Third People’s Hospital, The Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China
  • 6Department of Basic Medicine, Jiamusi University, Jiamusi, Heilongjiang, China
  • 7Institute for Infectious Disease, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China
  • 8Department of Infectious Diseases, Shenzhen Third People’s Hospital, The Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, Guangdong, China

A Correction on
HIV subtype-specific gp140-CD4 binding, Temsavir efficacy, and identification of novel adhesion inhibitors against Chinese HIV strains

By Liu T, Li X, Yang X, Zhang S, Wang Y, Zhang S, Cheng L, Tang S, Wang F, Zhao Y, Lu H and Wei L (2025) Front. Immunol. 16:1648546. doi: 10.3389/fimmu.2025.1648546

An incorrect number was provided for the Shenzhen Science and Technology Innovation Program. The correct number is “(KCXFZ20211020163544002)”.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: HIV-1, gp140-CD4 binding, Temsavir, CRF subtypes, adhesion inhibitors

Citation: Liu T, Li X, Yang X, Zhang S, Wang Y, Zhang S, Cheng L, Tang S, Wang F, Zhao Y, Lu H and Wei L (2026) Correction: HIV subtype-specific gp140-CD4 binding, Temsavir efficacy, and identification of novel adhesion inhibitors against Chinese HIV strains. Front. Immunol. 17:1795238. doi: 10.3389/fimmu.2026.1795238

Received: 24 January 2026; Accepted: 29 January 2026;
Published: 04 February 2026.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2026 Liu, Li, Yang, Zhang, Wang, Zhang, Cheng, Tang, Wang, Zhao, Lu and Wei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Fuxiang Wang, MTM5Mjc0ODYwNzdAMTYzLmNvbQ==; Yao Zhao, emhhb3lhb0BzaGFuZ2hhaXRlY2guZWR1LmNu; Hongzhou Lu, bHVob25nemhvdUBmdWRhbi5lZHUuY24=; Lanlan Wei, d2VpbGFubGFuXzExMTlAMTYzLmNvbQ==

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.